Press Releases

First Previous Next End

May 4, 2016

Provectus Biopharmaceuticals Will Hold Its 2016 First Quarter Business Update Conference Call on Tuesday, May 10, 2016, at 4 PM Eastern Daylight Time

Provectus announced today that it will host its 2016 first quarter business update conference call on Tuesday, May 10, 2016 at 4 pm Eastern Daylight Time.

April 28, 2016

Provectus Biopharmaceuticals Announces Publication of Two Abstracts on Research into IL PV-10 for Melanoma in Special Issue of ANZ Journal of Surgery

Provectus announced today that two abstracts related to research into IL PV-10 for treatment for melanoma have been published in a special issue of the ANZ Journal of Surgery detailing the Royal Australasian College of Surgeons 85th Annual Scientific Congress, 2-6 May 2016, in Queensland, Australia.

April 27, 2016

Provectus Biopharmaceuticals to Participate in Panel at Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact

Provectus today announced that it will be participating in a panel discussion at Cellular Horizons: The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact. The conference will be held April 28-30, 2016, in Vatican City, and hosted by the Vatican's Pontifical Council for Culture, The Stem For Life Foundation and the STOQ (Science, Theology and the Ontological Quest) Foundation.

April 22, 2016

Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016

Provectus announced today that researchers from Moffitt Cancer Center in Tampa, Florida, presented a poster titled, "T cell Mediated Immunity After Combination Therapy with Intralesional PV-10 and Co-Inhibitory Blockade in a Melanoma Model," at the American Association for Cancer Research (AACR) Annual Meeting 2016, held at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

April 20, 2016

Provectus Biopharmaceuticals Reports Trials in Progress Abstract Accepted for Poster Presentation at ASCO Annual Meeting

Provectus today announced that an abstract titled Intralesional rose bengal for treatment of melanoma has been accepted for a poster presentation at the annual meeting of the American Society of Clinical Oncology being held in Chicago June 3-7, 2016.

March 30, 2016

Provectus Biopharmaceuticals, Inc. Reports Fourth Quarter and Year End 2015 Financial Results

Provectus today announced its financial results for the fourth quarter and year ended December 31, 2015.

March 24, 2016

Provectus Biopharmaceuticals to Host Its Quarterly Year-End 2015 Financial Business Update Conference Call Wednesday, March 30, 2016 at 4 pm (EDT)

Provectus today announced that it will host its 2015 year-end quarterly financial business update conference call on Wednesday, March 30, 2016, at 4:00 p.m. Eastern Daylight Time.

March 18, 2016

Provectus Biopharmaceuticals Announces Abstract Publicly Available for Poster Presentation on PV-10 in Combination Therapy and T Cell Mediated Immunity

Provectus announced today that the abstract for an upcoming poster presentation of data on intralesional PV-10 and co-inhibitory blockade and mechanisms of T cell mediated immunity in a melanoma model is now publicly available.

March 16, 2016

Provectus Biopharmaceuticals Amends Protocol for Phase 3 Study of PV-10 in Treatment of Locally Advanced Cutaneous Melanoma

Provectus today announced that the protocol for its phase 3 clinical trial for PV-10 as an investigational treatment for melanoma has been amended to reflect current and evolving standards of care and applicable patient population for a global study in melanoma.

March 16, 2016

Provectus Announces Results of Internal Investigation

Provectus announced today that the Audit Committee of its Board of Directors (the "Committee") has conducted an internal investigation that was initiated by the Committee in connection with the February 2016 resignation of the Company's former chief executive officer, Dr. H. Craig Dees. The Committee retained independent counsel and an advisory firm with forensic accounting expertise to assist the Committee in conducting the investigation. As part of the investigation, the Committee reviewed the Company's financial policies and procedures, including management expenses.

March 11, 2016

Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Wednesday, March 16, 2016, at 4 PM EDT

Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Wednesday, March 16, 2016, at 4:00 p.m. Eastern Daylight Time.

March 10, 2016

Provectus Biopharmaceuticals Changes Date of Quarterly Business Update Conference Call to Wednesday March 16, 2016, at 4 pm (EDT)

Provectus today announced that it is changing the date for its fourth quarter and year-end conference call to Wednesday March 16, 2016, from March 10, 2016. The call will take place at 4 pm EDT that day.

March 1, 2016

Provectus Biopharmaceuticals Awarded Patent Extending Protection of the PV-10 Manufacturing Process

Provectus today announced that it has received a patent from the U.S. Patent and Trademark Office, U.S. Patent No. 9,273,022.

February 29, 2016

Provectus Biophamaceuticals to Host Business Update Conference Call Tuesday, March 1, 2016, at 4 PM EST

Provectus today announced that it will host a conference call at 4 PM Eastern Standard Time, on Tuesday, March 1, 2016. The purpose of the call will be to discuss recently announced changes in the Company's leadership stemming from the resignation of H. Craig Dees, PhD, as Chairman and CEO.

February 29, 2016

Provectus Biopharmaceuticals Initiating Phase 1 Study of PV-10 in Neuroendicrine Tumors Metastatic to Liver

Provectus today announced that it is initiating a protocol titled, "A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products."

February 29, 2016

Provectus Biopharmaceuticals Announces Leadership Changes

Provectus announced today several leadership changes following the resignation of one of its Co-Founders and its Chairman and CEO, H. Craig Dees, PhD.

February 14, 2016

Provectus Biopharmaceuticals Announces Data on PV-10 and Co-Inhibitory Blockade to Be Presented at American Association for Cancer Research Annual Meeting 2016

Provectus today announced that data on intralesional PV-10 and co-inhibitory blockade in a melanoma model will be presented at the American Association for Cancer Research's ("AACR") Annual Meeting 2016 on Wednesday, April 20, 2016, from 8 am to 12 Noon Central Standard Time.

February 10, 2016

Provectus Biopharmaceuticals to Host Fourth Quarter, Year-End 2015 Conference Call Thursday, March 10, 2016, at 4 PM EST

Provectus today announced that it will host its fourth quarter and year-end 2015 conference call on Thursday, March 10, 2016, at 4:00 p.m. Eastern Standard Time.

February 3, 2016

Data on Immunology Effects of Provectus Biopharmaceuticals PV-10 in Colon Cancer Presented at 11th Annual ASC Meeting

Provectus today announced data discussing the immunologic effects of PV-10 on colon cancer cells were presented yesterday at the 11th Annual Academic Surgical Congress in Jacksonville, Florida.

February 2, 2016

Provectus Biopharmaceuticals to Present at 18th Annual BIO CEO & Investor Conference

Provectus today announced that it will present at the 18th Annual BIO CEO & Investor Conference.

First Previous Next End